WO2009082743A3 - Genetic markers for schizophrenia and bipolar disorder - Google Patents
Genetic markers for schizophrenia and bipolar disorder Download PDFInfo
- Publication number
- WO2009082743A3 WO2009082743A3 PCT/US2008/088061 US2008088061W WO2009082743A3 WO 2009082743 A3 WO2009082743 A3 WO 2009082743A3 US 2008088061 W US2008088061 W US 2008088061W WO 2009082743 A3 WO2009082743 A3 WO 2009082743A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bipolar disorder
- schizophrenia
- genetic markers
- predict
- hpcall
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/523,243 US8460868B2 (en) | 2007-12-24 | 2008-12-22 | Genetic markers for schizophrenia and bipolar disorder |
EP08865698.8A EP2235209B1 (en) | 2007-12-24 | 2008-12-22 | Genetic markers for schizophrenia and bipolar disorder |
CA2709479A CA2709479A1 (en) | 2007-12-24 | 2008-12-22 | Genetic markers for schizophrenia and bipolar disorder |
AU2008340209A AU2008340209A1 (en) | 2007-12-24 | 2008-12-22 | Genetic markers for schizophrenia and bipolar disorder |
IL206617A IL206617A0 (en) | 2007-12-24 | 2010-06-24 | Genetic markers for scihizophrenia and bipolar disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1656307P | 2007-12-24 | 2007-12-24 | |
US61/016,563 | 2007-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009082743A2 WO2009082743A2 (en) | 2009-07-02 |
WO2009082743A3 true WO2009082743A3 (en) | 2009-11-19 |
Family
ID=40637705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/088061 WO2009082743A2 (en) | 2007-12-24 | 2008-12-22 | Genetic markers for schizophrenia and bipolar disorder |
Country Status (6)
Country | Link |
---|---|
US (1) | US8460868B2 (en) |
EP (1) | EP2235209B1 (en) |
AU (1) | AU2008340209A1 (en) |
CA (1) | CA2709479A1 (en) |
IL (1) | IL206617A0 (en) |
WO (1) | WO2009082743A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2581457A3 (en) | 2008-01-17 | 2013-07-17 | Suregene LLC | Genetic markers of mental illness |
EP2344672B8 (en) | 2008-09-25 | 2014-12-24 | SureGene LLC | Genetic markers for optimizing treatment for schizophrenia |
US7951543B2 (en) * | 2009-11-04 | 2011-05-31 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7951542B2 (en) | 2009-11-04 | 2011-05-31 | Surgene, LLC | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7985551B2 (en) | 2009-11-04 | 2011-07-26 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7972793B2 (en) * | 2009-11-04 | 2011-07-05 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype |
US7932042B1 (en) | 2010-10-13 | 2011-04-26 | Suregene, Llc | Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US20200168317A1 (en) | 2018-08-22 | 2020-05-28 | Centre For Addiction And Mental Health | Tool for assisting individuals experiencing auditory hallucinations to differentiate between hallucinations and ambient sounds |
CN115667546A (en) * | 2020-02-05 | 2023-01-31 | 新加坡科技研究局 | Biomarkers for predicting risk of parkinson's disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000882A1 (en) * | 1999-06-25 | 2001-01-04 | The Trustees Of The University Of Pennsylvania | Molecular correlates of schizophrenia and methods of diagnosing schizophrenia via these molecular correlates |
EP1266906A1 (en) * | 2001-06-13 | 2002-12-18 | Millennium Pharmaceuticals, Inc. | 46584, a human transporter family member and uses therefor |
WO2004051222A2 (en) * | 2002-12-03 | 2004-06-17 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
US20050209181A1 (en) * | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
WO2007100913A2 (en) * | 2006-02-28 | 2007-09-07 | The Regents Of The University Of California | Genes differentially expressed in bipolar disorder and/or schizophrenia |
WO2007145992A2 (en) * | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5800998A (en) * | 1996-11-12 | 1998-09-01 | Millennium Pharmaceuticals, Inc. | Assays for diagnosing type II diabetes in a subject |
WO2003039234A2 (en) * | 2001-11-06 | 2003-05-15 | David Pickar | Pharmacogenomics-based system for clinical applications |
CA2592473A1 (en) * | 2004-12-30 | 2006-07-06 | University Of Louisville Research Foundation, Inc. | Genetic markers of schizophrenia |
WO2009008896A1 (en) | 2007-07-06 | 2009-01-15 | University Of Louisville Research Foundation, Inc. | Genetic markers of schizophrenia |
-
2008
- 2008-12-22 AU AU2008340209A patent/AU2008340209A1/en not_active Abandoned
- 2008-12-22 CA CA2709479A patent/CA2709479A1/en not_active Abandoned
- 2008-12-22 WO PCT/US2008/088061 patent/WO2009082743A2/en active Application Filing
- 2008-12-22 EP EP08865698.8A patent/EP2235209B1/en not_active Not-in-force
- 2008-12-22 US US12/523,243 patent/US8460868B2/en active Active
-
2010
- 2010-06-24 IL IL206617A patent/IL206617A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000882A1 (en) * | 1999-06-25 | 2001-01-04 | The Trustees Of The University Of Pennsylvania | Molecular correlates of schizophrenia and methods of diagnosing schizophrenia via these molecular correlates |
EP1266906A1 (en) * | 2001-06-13 | 2002-12-18 | Millennium Pharmaceuticals, Inc. | 46584, a human transporter family member and uses therefor |
WO2004051222A2 (en) * | 2002-12-03 | 2004-06-17 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
US20050209181A1 (en) * | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
WO2007100913A2 (en) * | 2006-02-28 | 2007-09-07 | The Regents Of The University Of California | Genes differentially expressed in bipolar disorder and/or schizophrenia |
WO2007145992A2 (en) * | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
Non-Patent Citations (10)
Title |
---|
BERNSTEIN HANS-GERT ET AL: "Brain region-specific changes in the expression of calcium sensor proteins after repeated applications of ketamine to rats.", NEUROSCIENCE LETTERS, vol. 339, no. 2, 20 March 2003 (2003-03-20), pages 95 - 98, XP002529795, ISSN: 0304-3940 * |
CICHON S ET AL: "Pharmacogenetics of schizophrenia.", AMERICAN JOURNAL OF MEDICAL GENETICS SPRING 2000, vol. 97, no. 1, April 2000 (2000-04-01), pages 98 - 106, XP002529793, ISSN: 0148-7299 * |
DATABASE GENECARDS [online] "HPCAL 1, HIPPOCALCIN-LIKE 1", XP002529796, retrieved from HTTP://WWW.GENECARDS.ORG/CGI-BIN/CARDDISP.PL?GENE=HPCAL1&SEARCH=HPCAL1&SNP=751#SNP Database accession no. GC02P010393 * |
DATABASE GENECARDS [online] "SV2C synaptic vesicle glycoprotein 2C", XP002545132, retrieved from HTTP://WWW.GENECARDS.ORG/CGI-BIN/CARDDISP.PL?GENE=SV2C&SEARCH=SV2C&SNP=1499#SNP Database accession no. GC05P075414 * |
FREUDENBERG-HUA Y ET AL: "Systematic investigation of genetic variability in 111 human genes-implications for studying variable drug response.", THE PHARMACOGENOMICS JOURNAL 2005, vol. 5, no. 3, 2005, pages 183 - 192, XP008106631, ISSN: 1470-269X * |
HANS-GERT BERNSTEIN ET AL: "Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia", JOURNAL OF NEUROCYTOLOGY, KLUWER ACADEMIC PUBLISHERS, BO, vol. 30, no. 8, 1 August 2001 (2001-08-01), pages 661 - 670, XP019214056, ISSN: 1573-7381 * |
MARCHECO-TERUEL B ET AL: "A genome-wide linkage search for bipolar disorder susceptibility loci in a large and complex pedigree from the eastern part of Cuba.", AMERICAN JOURNAL OF MEDICAL GENETICS. PART B, NEUROPSYCHIATRIC GENETICS : THE OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY OF PSYCHIATRIC GENETICS, vol. 141B, no. 8, 5 December 2006 (2006-12-05), pages 833 - 843, XP002545160, ISSN: 1552-4841 * |
SHERRINGTON R ET AL: "LOCALIZATION OF A SUSCEPTIBILITY LOCUS FOR SCHIZOPHRENIA ON CHROMOSOME 5", NATURE, vol. 336, no. 6195, 1988, LONDON, pages 164 - 167, XP002545159, ISSN: 0028-0836 * |
STÖBER GERALD ET AL: "Association study of 5'-UTR polymorphisms of the human dopamine transporter gene with manic depression.", BIPOLAR DISORDERS OCT 2006, vol. 8, no. 5 Pt 1, October 2006 (2006-10-01), pages 490 - 495, XP002529794, ISSN: 1398-5647 * |
ZHANG AIPING ET AL: "Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.", PHARMACOGENOMICS OCT 2007, vol. 8, no. 10, October 2007 (2007-10-01), pages 1337 - 1345, XP008106676, ISSN: 1744-8042 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008340209A1 (en) | 2009-07-02 |
US20100151461A1 (en) | 2010-06-17 |
EP2235209B1 (en) | 2014-02-12 |
US8460868B2 (en) | 2013-06-11 |
IL206617A0 (en) | 2010-12-30 |
CA2709479A1 (en) | 2009-07-02 |
WO2009082743A2 (en) | 2009-07-02 |
EP2235209A2 (en) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009082743A3 (en) | Genetic markers for schizophrenia and bipolar disorder | |
AU2018260866A1 (en) | Selective reduction of allelic variants | |
EP2344672B8 (en) | Genetic markers for optimizing treatment for schizophrenia | |
WO2009070805A3 (en) | Mir-124 regulated genes and pathways as targets for therapeutic intervention | |
IL211140A (en) | Method of determining risk of alzheimer's disease based on the presence or absence of variants in the tomm40 gene | |
ZA200810105B (en) | Means for controlling the progression of myopia | |
WO2008137236A3 (en) | Treatment of age-related macular degeneration using inhibitors of complement factor d | |
WO2009059318A3 (en) | Genes and polymorphisms associated with amd | |
MX2007009565A (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration. | |
WO2014200952A3 (en) | Genetic markers of antipsychotic response | |
WO2010124264A3 (en) | Genetic variants in angiogenesis pathway associated with clinical outcome | |
HK1137194A1 (en) | Compositions and methods for inhibiting expression of a gene from the ebola | |
WO2008085797A8 (en) | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION | |
EP2581453A3 (en) | Genetic Markers of Mental Illness | |
EP1831403A4 (en) | Genetic markers of schizophrenia | |
WO2012018613A3 (en) | Genetic make-up modifies cancer outcome | |
WO2013181125A3 (en) | Methods of detecting single nucleotide polymorphisms at codon 600 of human braf | |
WO2008088861A3 (en) | Gene polymorphisms predictive for dual tki therapy | |
WO2008088860A3 (en) | Polymorphisms in the egfr pathway as markers for cancer treatment | |
ATE534738T1 (en) | MIR-126-REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTIONS | |
WO2007095185A3 (en) | Variants in complement regulatory genes predict age-related macular degeneration | |
WO2008076449A3 (en) | Predicting a response to olanzapine | |
WO2011020075A3 (en) | Amelogenin snp on chromosome x | |
ES2344396A1 (en) | Genetic markers of the risk of suffering from restenosis | |
GB2489180A (en) | Method of predicting capecitabine toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08865698 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12523243 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2709479 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008865698 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008340209 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008340209 Country of ref document: AU Date of ref document: 20081222 Kind code of ref document: A |